Methylenedioxyallylamphetamine

Methylenedioxyallylamphetamine

Names
IUPAC name N-[1-(1,3-Benzodioxol-5-yl)propan-2-yl]prop-2-en-1-amine
Identifiers
CAS Number	74698-45-6
3D model (JSmol)	Interactive image
ChemSpider	21106331
PubChem CID	44719581
CompTox Dashboard (EPA)	DTXSID40660369
InChI InChI=1S/C13H17NO2/c1-3-6-14-10(2)7-11-4-5-12-13(8-11)16-9-15-12/h3-5,8,10,14H,1,6-7,9H2,2H3 Key: BMKCDDFQEGYEJC-UHFFFAOYSA-N InChI=1/C13H17NO2/c1-3-6-14-10(2)7-11-4-5-12-13(8-11)16-9-15-12/h3-5,8,10,14H,1,6-7,9H2,2H3 Key: BMKCDDFQEGYEJC-UHFFFAOYAO
SMILES C1=C2C(=CC=C1CC(C)NCC=C)OCO2
Properties
Chemical formula	C13H17NO2
Molar mass	219.284 g·mol−1
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).

Methylenedioxyallylamphetamine (MDAL or 3,4-methylenedioxy-N-allylamphetamine) is a lesser-known psychedelic drug. It is also the N-allyl derivative of 3,4-methylenedioxyamphetamine (MDA). MDAL was first synthesized by Alexander Shulgin. In his book PiHKAL, the minimum dosage is listed as 180 mg, and the duration unknown.^[1] MDAL produces few to no effects on its own, but may enhance the effects of LSD. Very little data exists about the pharmacological properties, metabolism, and toxicity of MDAL.

Legality

United Kingdom

This substance is a Class A drug in the Drugs controlled by the UK Misuse of Drugs Act.^[2]

See also

• Phenethylamine
• MDPR

References